July 27, 2016 5:45 AM ET

Capital Markets

Company Overview of Polaris Partners

Company Overview

Polaris Partners is a venture capital and private equity firm specializing in investments in all company lifecycle stages including earliest startup, seed, early stage, mid venture, late venture, first round investments, later stage, mature, emerging growth, expansion, growth capital, recapitalization, liquidity, turnarounds, leveraged buyouts, and minority growth equity investments in high-growth middle market companies. It typically invests in technology, energy, healthcare, life sciences, business services, and consumer sectors. Within technology the firm invests in seed, early stage, later rounds, and growth equity, in the cloud infrastructure; SaaS; software; e-commerce; consumer Intern...

1000 Winter Street

Suite 3350

Waltham, MA 02451

United States

Founded in 1996





Key Executives for Polaris Partners

Co-Founder, Founding Partner, and General Partner
Age: 65
Co-Founder, Founding Partner, and General Partner
Age: 60
Co-Founder, Venture Partner, and Founding Partner Emeritus
Chief Financial Officer
General Partner, Managing Partner, and Partner
Compensation as of Fiscal Year 2016.

Polaris Partners Key Developments

Polaris Partners To Raise Funds

Polaris Partners is looking to raise $400 million for its eighth fund, AltAssets can reveal.

Polaris Partners Presents at The 9th annual New England Venture Summit, Dec-10-2014

Polaris Partners Presents at The 9th annual New England Venture Summit, Dec-10-2014 . Venue: Hilton Boston Dedham, 25 Allied Drive, Dedham, MA 02026, United States. Speakers: Patrick Kinsel, Venture Partner.

Polaris Partners Appoints Amy Schulman as a Venture Partner and Chief Executive Officer of Arsia Therapeutics

Polaris Partners announced the hiring of biopharmaceutical executive Amy Schulman as a Venture Partner, based out of Boston. Schulman, who most recently served as General Counsel, EVP, and Business Unit Lead of Pfizer Consumer Healthcare, will apply decades of experience to the Polaris healthcare portfolio. She will also assume the role of Chief Executive Officer of Arsia Therapeutics, an early stage Polaris-backed company co-founded by Dr. Robert Langer and Polaris Partner Alan Crane. In addition to taking on the CEO role at Arsia, Schulman is expected to assume a number of Polaris company board seats and continue to serve on the board of Cambridge-based Alnylam. At Arsia, she will work closely with Alan Crane who remains with the company as Chairman of the Board.

Similar Private Companies By Industry

Company Name Region
@Visory LLC United States
1 Road Partners LLC United States
11T Partners, LLC United States
13D Research (USVI) LLC. United States
1509225 Ontario, Inc. United States

Recent Private Companies Transactions

July 13, 2016
Imprivata, Inc.
Private Placement
June 29, 2016
Morphic Rock Therapeutic, Inc.
Private Placement
June 17, 2016
US HealthVest, LLC

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Polaris Partners, please visit www.polarispartners.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.